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SIRT1–NOX4 signaling axis regulates cancer cachexia
Aneesha Dasgupta1, Surendra K. Shukla2, Enza Vernucci2, Ryan J. King2, Jaime Abrego2, Scott E. Mulder1, Nicholas J. Mullen2, Gavin Graves2,
Kyla Buettner2, Ravi Thakur2, Divya Murthy2, Kuldeep S. Attri2, Dezhen Wang2, Nina V. Chaika2, Camila G. Pacheco2, Ibha Rai2,
Dannielle D. Engle3, Paul M. Grandgenett2, Michael Punsoni4, Bradley N. Reames5, Melissa Teoh-Fitzgerald1, Rebecca Oberley-Deegan1, Fang Yu6,
Kelsey A. Klute7, Michael A. Hollingsworth2, Matthew C. Zimmerman8, Kamiya Mehla2, Junichi Sadoshima9, David A. Tuveson3, and
Pankaj K. Singh1,2,4
Approximately one third of cancer patients die due to complexities related to cachexia. However, the mechanisms of cachexia
and the potential therapeutic interventions remain poorly studied. We observed a significant positive correlation between
SIRT1 expression and muscle fiber cross-sectional area in pancreatic cancer patients. Rescuing Sirt1 expression by exogenous
expression or pharmacological agents reverted cancer cell–induced myotube wasting in culture conditions and mouse models.
RNA-seq and follow-up analyses showed cancer cell–mediated SIRT1 loss induced NF-κB signaling in cachectic muscles that
enhanced the expression of FOXO transcription factors and NADPH oxidase 4 (Nox4), a key regulator of reactive oxygen
species production. Additionally, we observed a negative correlation between NOX4 expression and skeletal muscle fiber
cross-sectional area in pancreatic cancer patients. Knocking out Nox4 in skeletal muscles or pharmacological blockade of Nox4
activity abrogated tumor-induced cachexia in mice. Thus, we conclude that targeting the Sirt1–Nox4 axis in muscles is an
effective therapeutic intervention for mitigating pancreatic cancer–induced cachexia.
Introduction
Cancer cachexia is a metabolic syndrome that contributes to
significantmortality in cancer patients (Baracos et al., 2018). It is
defined as the loss in skeletal muscle mass that cannot be fully
reversed by conventional nutritional therapy and leads to pro-
gressive functional impairment (Fearon et al., 2011). While the
incidence varies across different cancers, pancreatic ductal ad-
enocarcinoma (PDAC) patients show the highest prevalence of
cancer cachexia (Baracos et al., 2018). According to an estimate,
one third of pancreatic cancer patients die directly due to
cachexia-associated complications, entailing respiratory or cardiac
failure (Bachmann et al., 2009). Cancer cachexia is also associated
with poor response to chemotherapy and decreased overall sur-
vival (Bachmann et al., 2008; Dewys et al., 1980). Until now, the
manifestation of cancer cachexia has been attributed to systemic
inflammation caused by the host body and tumor-derived cyto-
kines (Ebrahimi et al., 2004; Fearon et al., 2006). However, there
are no Food and Drug Administration–approved drugs to mitigate
cancer-induced cachexia. Thus, there is an urgent need to find
more effective therapeutic targets against cancer cachexia.
The silent information regulator 2 (SIR2) family of pro-
teins, called sirtuins, are primarily NAD+-dependent protein
deacylases and mono-[ADP-ribosyl] transferases that link
changes in energy metabolism to transcriptional reprogram-
ming (Imai et al., 2000). These enzymes respond to the
availability of NAD+ which is an important currency in energy
homeostasis and cellular metabolism (Imai and Guarente,
2016). There are seven mammalian sirtuins, which are also
referred to as class III histone deacetylases (Bosch-Presegue´
and Vaquero, 2011). Sirtuins vary in their subcellular locali-
zation and their preferred substrates, which in turn define
their specific roles in cellular homeostasis (German and Haigis,
2015). Mammalian sirtuins are involved in various functions
such as chromatin regulation, metabolic homeostasis, and cell
survival under stress (Bosch-Presegue´ and Vaquero, 2011). In-
troducing an additional copy of sir-2 gene enhances the lifespan
of Caenorhabditis elegans by 50%, and its inhibition leads to a
shortened lifespan (Tissenbaum and Guarente, 2001), implying
an essential role of sirtuins in aging.
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Among all the sirtuins, Sirt1 has also been illustrated to play a
role in muscle physiology (Pardo and Boriek, 2011; Sharples
et al., 2015; Vinciguerra et al., 2010) by enhancing mitochon-
drial fatty acid oxidation through deacetylating peroxisome
proliferator-activated receptor-gamma coactivator 1-α (PGC1-α;
Amat et al., 2009). Sirtuins also plays a critical role in balancing
muscle cell differentiation and proliferation (Fulco et al., 2008;
Fulco et al., 2003; Rathbone et al., 2009). It is now well estab-
lished that increased expression of muscle-specific ubiquitin
ligases muscle ring finger 1 (MuRF1) and muscle atrophy F-box
(MAFbx/Atrogin-1) is a hallmark of muscle atrophy (Bodine
et al., 2001; Gomes et al., 2001). These genes are activated by
the FOXO (Forkhead box O) family of transcription factors, in-
cluding FOXO1 and FOXO3 (Mammucari et al., 2007; Zhao et al.,
2007). Activities of FOXO1 and FOXO3 are regulated by cycles of
acetylation and deacetylation, the latter being mediated by Sirt1
(Yang et al., 2005). Additionally, decreased SIRT1 in muscle
following prolonged fasting correlated with an increase in the
levels of ubiquitin ligases (Lee and Goldberg, 2013). Intriguingly,
our current study demonstrated a tumor-induced decrease in
Sirt1 in the muscles of cancer patients and spontaneous PDAC
mouse models.
In this study, we elucidated the potential utility of targeting
sirtuins in combating cancer cachexia. We investigated whether
activation of sirtuins in the muscle, irrespective of the effects in
the tumor, would be sufficient to combat muscle wasting.
Moreover, there is growing evidence of oxidative damage in
cancer-induced cachexia, and studies have demonstrated suc-
cessful mitigation of cancer-induced muscle atrophy by the use
of antioxidants (A´brigo et al., 2018; Buck and Chojkier, 1996;
Gomes-Marcondes and Tisdale, 2002). Since SIRT1 has been
shown to inhibit oxidative stress (Salminen et al., 2013; Zhang
et al., 2017), we evaluated its potential to combat oxidative
stress-related atrophy in cancer-induced cachexia. Our findings
demonstrate that SIRT1 stabilization in the skeletal muscles can
mitigate cancer-induced muscle wasting. We have also estab-
lished a novel function of SIRT1 in the regulation of NADPH
oxidase 4 (Nox4) in the muscle tissues of tumor-bearing mice.
Furthermore, pharmacological inhibition or genetic deletion of
Nox4 enzyme abrogated cancer-induced muscle wasting in
tumor-bearing mice and provided a survival benefit.
Results
SIRT1 expression decreases in cancer-induced cachexia
To evaluate whether sirtuins are altered in cachexia, we mea-
sured the mRNA expression levels of the seven sirtuins in
the gastrocnemius muscles from 10-, 15-, and 25-wk-old
KrasLSL.G12D/+; p53LSL.R172H/+; Pdx1-Cre (KPC) spontaneous PDAC
tumor-bearing mouse model and littermate controls. Sirt1 ex-
pression was significantly decreased in gastrocnemius muscles
from KPC mice at 15 and 25 wk of age compared with control
mice (Fig. 1 A). However, we observed no significant alterations
in the other sirtuins, except for Sirt2, which was decreased in the
KPCmice muscles only at 25 wk of age (Fig. S1 A). Loss in muscle
weight was observed in the mice at 15 and 25 wk of age which
corresponded to decreased Sirt1 expression and increased tumor
progression (Fig. S1, B and C). We also observed an increase in
atrophy markers in the muscles of the mice at 15 and 25 wk of
age (Fig. S1 D). Concordantly, muscles collected from C26 tumor-
bearing mice also demonstrated a decrease in Sirt1 expression,
with no significant decrease in the other sirtuins (Fig. S1 E).
We next assessed if PDAC patients had a similar decrease in
SIRT1 expression in skeletal muscles. To achieve this, we per-
formed immunohistochemical analysis for SIRT1 expression on
54 pancreatic cancer patient skeletal muscle sections obtained
from the Rapid Autopsy Program at the University of Nebraska
Medical Center (UNMC; Fig. 1 B). We scored the patient muscle
samples for SIRT1 staining and observed a significant positive
correlation between muscle cross-section area and SIRT1 stain-
ing after adjusting the P value for confounding factors (Fig. 1 C
and Table S1).
Cancer cell–secreted factors diminish Sirt1 expression in C2C12
myotubes
Reasoning that the muscle cells of PDAC patients and tumor-
bearing mice respond to factors in the bloodstream, we sought
to determine if cancer cell–secreted factors could directly di-
minish Sirt1 expression in an in vitro C2C12 myotube model. To
achieve this, we treated C2C12 myotubes with conditioned me-
dia (CM) from human (S2-013 and T3M4) and mouse (KPC1245
and KPC1199) pancreatic cancer cell lines. We observed that Sirt1
mRNA levels decreased in C2C12 myotubes upon treatment with
PDAC cell line CM (Fig. 1 D). No other sirtuin showed consis-
tently altered expression in this system (Fig. S2 A). Decreased
Sirt1 expression also correlated with decreased SIRT1 activity, as
measured with fluorescence-based activity assays (Fig. 1 D and
Fig. S2 B). To exclude the possibility that nutrient deprivation
might be driving myotube atrophy in vitro, we performed me-
tabolomics analysis on DMEM, PDAC cell CM, and pancreatic
epithelial cell (HPNE)–CM to evaluate the nutrient levels (Fig. S2
C). We then supplemented S2-013 CM with all nutrients that
were decreased at least 25% comparedwith DMEM to bring their
levels back up to those in control conditions. We observed no
rescue in the cachectic phenotype with the supplemented CM,
implying that nutrient starvation is not responsible for myotube
thinning (Fig. S2, D and E). Thus, nutrient depletion is not the
cause of CM-induced cachexia in our in vitro model.
Exogenous expression or stabilization of SIRT1 expression
impedes myotube degeneration and cachexia
To test if Sirt1 stabilization rescues the cachectic phenotype, we
overexpressed Sirt1 by adenoviral transduction in C2C12-derived
myotubes and then treated them with cancer cell CM for 24 h.
Sirt1 overexpression ameliorated the cachectic phenotype by
every metric that was tested, including myotube thickness
(Fig. 1, E and F), total protein content (Fig. 1 G), myosin heavy
chain expression (Fig. 1 H), and mRNA expression of Trim63
and Fbxo32 muscle-specific ubiquitin ligases (Fig. 1, I and J).
These changes were not caused by myotube apoptosis, as cas-
pase 3/7 activity assays showed no increase upon CM treatment
(Fig. S2 E).
Next, we evaluated if enhancing SIRT1 levels with a phar-
macologically relevant compoundwould prevent skeletal muscle
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wasting. Previous studies have established that resveratrol
(3,5,49-trihydroxystilbene), a natural phytoalexin, increases the
deacetylase activity of SIRT1 (Howitz et al., 2003) and increases
SIRT1 expression (Dong et al., 2014; Lagouge et al., 2006; Wu
et al., 2015). Since we observed that Sirt1 levels were decreased
in cachectic muscles, we investigated if resveratrol could revert
the cachectic phenotype. Supplementing the cancer cell CMwith
resveratrol (50 µM) rescued C2C12 myotube degeneration in
Figure 1. Sirt1 expression decreases in cachectic muscles. (A) Sirt1mRNA expression in KPC mouse gastrocnemius muscles (n = 3) at 10, 15, and 25 wk after
birth. (B) Representative immunohistochemical micrographs of SIRT1 staining in skeletal muscles of pancreatic cancer patients. (C) Correlation of the average
skeletal muscle fiber cross section area with the SIRT1 histoscore in 54 muscle autopsy samples of pancreatic cancer patients. R depicts Pearson’s correlation
coefficient and P < 0.0001. (D) Sirt1 mRNA expression in myotubes treated with S2-013, T3M4, KPC1245, and KPC1199 CM for 24 h. (E–J) Brightfield mi-
croscopy images (at 200×; E), myotube width quantification (F), relative protein content (G), protein lysate immunoblot analysis of MyHC (H), and mRNA
expression of Trim63 (MuRF-1) and Fbxo32 (Atrogin-1; I and J) in C2C12 myotubes transfected with either adenoviral GFP or Sirt1 and treated with S2-013 and
T3M4-CM for 24 h. Scale bars represent 75 µm. Data are presented as mean ± SEM and were compared with Student’s t test (A), one-way ANOVA with
Dunnett’s (D), or Bonferroni’s (F, G, I, and J) multiple comparisons. *, P < 0.05; **, P < 0.01; ***, P < 0.001. ns, not significant. All the in vitro experiments were
verified in at least two independent experiments.
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culture conditions, as measured by myotube thickness (Fig. 2, A
and B) and myosin heavy chain expression (Fig. 2 C). Resveratrol
also diminished the cancer cell CM–induced protein expression of
ATROGIN-1 andMuRF1muscle-specific ubiquitin ligases (Fig. 2 C).
The mRNA levels of MuRF1 (Trim63) and Atrogin-1 (Fbxo32) were
also decreased upon addition of resveratrol to the CM (Fig. 2, D
and E). We also observed resveratrol-mediated rescue of Sirt1
mRNA levels in the myotubes upon treatment with CM (Fig. 2 F).
Systemic administration of pharmacological agents stabiliz-
ing/increasing Sirt1 expression could diminish cachexia by di-
rectly impacting Sirt1 levels in skeletal muscles or bymodulating
Sirt1 levels in tumor cells that may impact the cachectic secre-
tome of the latter. Hence, it was important to first evaluate the
effect of resveratrol on pancreatic cancer cell lines. Of note,
previous studies have demonstrated that resveratrol decreases
proliferation of some pancreatic cancer cells (Xu et al., 2015;
Yang et al., 2014; Zhou et al., 2011). To determine if treatment of
pancreatic cancer cell lines with resveratrol impacted cell pro-
liferation in our cell line models, we treated S2-013 and T3M4
cells with multiple doses of resveratrol. We observed that
treatment with resveratrol decreased cell proliferation in a dose-
dependent manner (Fig. 2 G). The decreased cell proliferation by
resveratrol was Sirt1 dependent, because Ex-527, a SIRT1 in-
hibitor (Oon et al., 2015), could rescue the decreased survival
(Fig. S3 A). To further test if SIRT1 contributed to the diminished
survival by resveratrol and develop a model to test the effect of
resveratrol on the muscle, independent of its effect on the tu-
mor, we generated SIRT1 knockdowns in S2-013 cells by lenti-
viral delivery of short hairpin RNAs against SIRT1. We used two
constructs targeting independent regions of SIRT1 (shSIRT1-A
and shSIRT1-B) for knocking down SIRT1 expression (Fig. 2 H).
We then investigated if SIRT1 knockdown altered the sensitivity
of cancer cells to resveratrol (25 µM) by performing MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
assays. We observed that SIRT1 knockdown cells lacked sensi-
tivity to resveratrol (Fig. 2 I). Cancer cell CM from the scrambled
control and the SIRT1 knockdown cell lines had similar effect on
the protein content of the myotubes, implying that modulation
of SIRT1 in the tumor has no impact on the myodegenerative
potential in vitro (Fig. 2 J).
Having established that S2-013 cell lines with stable SIRT1
knockdown are resistant to resveratrol, we next investigated if
increasing the expression of Sirt1 in skeletal muscles by re-
sveratrol would rescue cachexia in animal models, independent
of tumor burden. We implanted scrambled control and SIRT1
knockdown S2-013 cells orthotopically into the pancreas of
athymic nude mice and administered resveratrol (200 mg/kg)
daily by oral gavage, starting 6 d after implantation (Fig. 3 A).
Consistent with our in vitro results, we observed decreased tu-
mor weight and volume upon necropsy in resveratrol-treated
mice implanted with scrambled control cells, but not in those
implanted with SIRT1 knockdown cells (Fig. 3, B and C). We
noted decreased body weight and muscle weight in mice im-
planted orthotopically with tumor cells (Fig. 3, D and E), but not
in PBS-injected mice (Fig. S3 B). These results establish the
utility of mice implanted with SIRT1 knockdown S2-013 cells for
testing the muscle-intrinsic effects of resveratrol.
Using the control and SIRT1 knockdown S2-013 orthotopic
tumor models, we observed that resveratrol ameliorated the
PDAC cell–induced cachexia by all metrics tested, including body
weight (Fig. 3 D); gastrocnemius muscle weight and cross-
sectional area (Fig. 3, E and F); forelimb grip strength
(Fig. 3 G); body fat percentage (Fig. 3 H); muscle expression of
myosin heavy chain, ATROGIN-1, and MuRF1 (Fig. 3 I); and
adipose tissue expression of fat-wasting markers, including Zag
and Ucp2, but not Ucp1 and Ucp3 (Fig. S3 C). This profound
phenotypic reversal correlated with muscle Sirt1 stabilization
as measured by immunoblot and immunohistochemical stain-
ing (Fig. 3 I) and Fig. S3 D). Importantly, none of these pa-
rameters were significantly influenced by the SIRT1 status of
the implanted S2-013 cells or tumor burden at necropsy, sug-
gesting a tumor cell–independent mechanism for resveratrol-
mediated reversal of cachexia in tumor-bearing mice.
SIRT1 regulates NF-κB and FOXO transcription factors
To investigate the potential mechanism of action of resveratrol-
induced protection against muscle wasting, we performed RNA
sequencing (RNA-seq) analysis of myotubes treated with S2-
013-CM with or without resveratrol for 24 h. We performed
gene set enrichment analysis (GSEA) and determined the en-
richment for transcription factors in the transcription factor
gene set from TFactS (http://www.tfacts.org/) to evaluate the
significantly altered pathways in all the cohorts (Fig. 4 A). We
observed significant alterations in 9 out of 101 transcription
factor pathways (Fig. 4 B). Of note, we observed enrichment of
FOXO1 and FOXO3 transcription factor–regulated genes, which
include muscle-specific ubiquitin ligases (Reed et al., 2012;
Sandri et al., 2004; Fig. 4 C), and these enrichments were
abolished by resveratrol treatment. Additionally, the NF-κB
pathway, which has been shown to be a major player in the
development of cachexia (Han et al., 1999), was significantly up-
regulated, and this enrichment too was abrogated by resveratrol
treatment (Fig. 4 D). These results are in line with previous
publications demonstrating the regulation of NF-κB activity by
Sirt1-mediated deacetylation (Chen et al., 2016; Jang et al., 1997;
Kauppinen et al., 2013).
We validated the RNA-seq results by evaluating the mRNA
and protein levels of Foxo1 and Foxo3 in myotubes treated with
cancer cell CM with or without resveratrol. We observed that
resveratrol decreased the cancer cell CM–induced expression of
the genes encoding for FOXO transcription factors (Fig. 4 E).
Similar results were observed in the protein levels of FOXO1 and
FOXO3 (Fig. 4 F), confirming that resveratrol prevents muscle
wasting by modulating FoxO proteins. We also observed a de-
crease in the mRNA levels of the Foxo1 and Foxo3 upon Sirt1
overexpression in CM-treated myotubes (Fig. 4 G). These results
indicate that Sirt1 overexpression was sufficient to abrogate the
CM-induced expression of FOXO proteins.
A promoter-reporter assay with an NF-κB–responsive
promoter-luciferase reporter construct also showed that re-
sveratrol diminished the cancer cell CM–induced NF-κB tran-
scriptional activity in myotubes (Fig. 4 H). Previous studies have
demonstrated increased transcriptional activity of NF-κB upon
acetylation of p65 at lysine 310 (Chen et al., 2002). Since K310
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residue of p65 has been known to be deacetylated by SIRT1
(Ghisays et al., 2015), we evaluated K310 acetylation levels upon
treatment of myotubes with cancer cell CM with and without
resveratrol. We observed increased acetylation of p65 at lysine
310 upon cancer cell CM treatment, and the effect was abolished
by resveratrol treatment (Fig. 4 I). These data suggest that SIRT1-
mediated deacetylation of NF-κB counteracts cancer cell CM–
induced NF-κB transcriptional activity in myotubes.
Figure 2. Modulation of SIRT1 levels by resveratrol combats muscle wasting in vitro. (A) Brightfield microscopy images (at 200×) of myotubes treated
with S2-013 and T3M4 CM with and without resveratrol (50 µM) treatment for 24 h. Scale bars represent 50 µm. (B) Myotube width was measured by
ImageJ. Five measurements were taken along the length of each myotube. (C) Immunoblots of MyHC, Atrogin-1, and MuRF-1 in myotubes treated with S2-013
and T3M4 CM along with resveratrol treatment for 24 h. Tubulin was used as a loading control. Quantification of band intensity was performed via Li-Cor Image
Studio Lite and values normalized to the untreated control and to tubulin are indicated below the bands. (D–F) mRNA expression of Trim63 (MuRF-1), Fbxo32
(Atrogin-1), and Sirt1 in myotubes treated with S2-013 and T3M4 CM along with resveratrol (50 µM) for 24 h. (G) MTT assay demonstrating the dose-
dependent effect of resveratrol on S2-013 and T3M4 cell survival 72 h after treatment. (H) Immunoblot of SIRT1 in S2-013 cells. Tubulin was used as a loading
control. (I) Relative survival of S2-013 shScr, shSIRT1-A, and shSIRT1-B upon resveratrol treatment for 72 h (25 µM) by MTT assays. (J) Protein content in
myotubes treated with S2-013 shScr CM, S2-013 shSIRT1-A CM, S2-013 shSIRT1-B CM along with resveratrol (50 µM). All the experiments were performed at
least three times in triplicate. Data are mean ± SEM compared with one-way ANOVA with Bonferroni’s (B, D–F, and J) or Dunnett’s (G) multiple comparisons. A
two-way ANOVA with Bonferroni’s post-hoc analysis was used considering the interaction between treatment and cell line (I). *, P < 0.05; **, P < 0.01; ***, P <
0.001. All the in vitro experiments were verified in at least two independent experiments.
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Diminished SIRT1 expression facilitates Nox4 expression via
the induction of NF-κB
Oxidative stress plays very important role in muscle homeo-
stasis (Musaro` et al., 2010), and previous studies have estab-
lished an inverse relationship between SIRT1 and ROS levels in
neuronal cells (Khan et al., 2012). Hence, we investigated if di-
minished SIRT1 levels in cachectic muscles contributed to oxi-
dative damage, resulting in myodegeneration. We observed
increased ROS levels in the myotubes treated with cancer cell
CM, which was abolished by resveratrol treatment (Fig. 5 A).
Thus, we next evaluated the levels of the key enzymes respon-
sible for ROS homeostasis in the muscles of the tumor-bearing
mice treated with resveratrol (Fig. 5 B and Fig. S3 E). We ob-
served increased mRNA and protein expression levels of NADPH
oxidase 4 (Nox4) that were reversed by resveratrol treatment
(Fig. 5 B and Fig. S4 A). This is consistent with previous reports
showing regulation of Nox4 by NF-κB in different contexts
(Manea et al., 2010; Williams et al., 2012).
Overexpression of Sirt1 in C2C12 myotubes was sufficient
to decrease acetylation of p65 and diminish the induction of
Nox4 expression (Fig. S4 B), suggesting a direct role of SIRT1
in NOX4 regulation. To determine if Nox4 is directly regulated
by NF-κB in cachectic skeletal muscles, we performed chro-
matin immunoprecipitation (ChIP) for NF-κB (p65 subunit) in
Figure 3. SIRT1 stabilization in muscles regulates muscles wasting in vivo. (A) Schematic illustration of the treatment strategy. (B and C) Postnecropsy
measurements of S2-013 shScr (n = 10), shSIRT1-A (n = 10), and shSIRT1-B (n = 10) tumor weights (B) and tumor volumes (C). (D) Change in body weight
measurements of the tumor-bearing mice 21 d after implantation. (E) Postnecropsy gastrocnemius muscle weight from S2-013 shScr, S2-013 shSIRT1-A, and
S2-013 shSIRT1-B tumor-bearing mice. (F) Quantification of muscle fiber cross-sectional area in hematoxylin and eosin–stained muscle sections from tumor-
bearing mice. (G)Measurement of grip strength of the tumor-bearing mice 18 d after implantation. (H)Measurement of fat percentage of S2-013 shScr (n = 8),
S2-013 shSIRT1-A (n = 8), and S2-013 shSIRT1-B (n = 8) tumor-bearing mice by dual-energy x-ray absorptiometry scanning 18 d after implantation. (I) Im-
munoblots of muscle tissue extracts from the tumor-bearing mice treated with resveratrol or solvent control, showing regulation of MyHC, Atrogin-1, MuRF1,
and SIRT1. Tubulin was used as a loading control. All in vitro experiments were performed at least three times in triplicate. Data are mean ± SEM compared
with one-way ANOVA with Bonferroni’s multiple comparisons (B–H); *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure 4. SIRT1 modulates transcriptional regulation by NF-κB and FOXO proteins. (A) Schematic illustration of the flow chart of RNA-seq analysis of
myotubes treated with control, CM, or CMwith resveratrol (Res). (B)Heatmap showing the Z-score changes in the three comparisons. 9 out of 101 pathways in
the transcription factor database from TFactS were significantly altered. (C) GSEA plots of genes regulated by FOXO1 and FOXO3. The NESs for FOXO1 are 2.07
(CM treated vs. control) and −1.9 (CM + Res treated vs. CM treated) pathway. The NESs for FOXO3 are 2.5 (CM treated vs. control) and 1.6 (CM + Res treated
vs. CM treated). Green line indicates enrichment profile, black vertical lines indicate hits, and gray vertical lines indicate ranking metric scores. (D) GSEA plots
for NF-κB. NESs for NF-κB are 2.91 (CM treated vs. control) and 1.6 (CM + Res treated vs. CM treated). Green line indicates enrichment profile, black vertical
lines indicate hits, and gray vertical lines indicate ranking metric scores. (E) mRNA levels of Foxo1 and Foxo3 in myotubes upon treatment with tumor cell CM
and resveratrol (50 µM). (F) Immunoblots showing altered levels of FOXO1, FOXO3, and SIRT1 in myotubes treated with tumor cell CM and resveratrol (50 µM)
for 24 h. (G) Foxo1 and Foxo3mRNA analysis of myotubes expressing adenovirally transduced (Ad) GFP control or SIRT1 upon treatment with tumor cell CM for
24 h. (H) Luciferase assay to measure NF-κB–responsive promoter-luciferase reporter activity upon treatment of myotubes with cancer cell CM with and
without resveratrol (50 µM) for 6 h. (I) Immunoblot analysis of acetylated and total p65 subunit of NF-κB in myotubes treated with cancer cell CM with and
without resveratrol (50 µM) for 24 h. Data are mean ± SEM compared with one-way ANOVA with Bonferroni’s multiple comparisons (E, G, and H). *, P < 0.05;
**, P < 0.01; ***, P < 0.001. The in vitro experiments were verified in at least two independent experiments.
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the promoter region of Nox4 in C2C12 myotubes. We found
increased occupancy of p65 at two consensus NF-κB response
elements upon treatment of myotubes with S2-013- and
T3M4-CM, and this promoter occupancy was reversed by
resveratrol treatment (Fig. 5 C). We also used a cell permeable
NF-κB essential modulator (NEMO)–binding domain (NBD)
peptide that can block the activation of the IκB kinase complex
and thereby inhibit NF-κB activity (Strickland and Ghosh,
2006). The NBD peptide abrogated the cancer cell CM–
induced expression of Nox4 and myotube atrophy (Fig. 5 D and
Fig. S4 C).
Further supporting the role of Nox4 in cachexia, we observed
a significant increase in Nox4 levels, along with Foxo1, Foxo3,
MuRF1 (Trim63), and Atrogin-1 (Fbxo32) in the muscles of 25-
wk-old KPC mice (Fig. 5 E) and C26 tumor-bearing mice (Fig.
S4 D) compared with littermate and non–tumor-bearing
controls, respectively. In agreement with these results, over-
expression of NOX4 in C2C12 myotubes via adenoviral infection
led to myotube atrophy, as measured by myotube width
(Fig. 5 F), MyHC expression (Fig. 5 G), and expression of Foxo
genes (Fig. 5 H). These results establish the critical role of
Nox4 in inducing the cachectic phenotype. In line with our
results showing a role of SIRT1 in NOX4 regulation, over-
expression of Sirt1 was sufficient to down-regulate the cancer
cell CM–induced Nox4 expression in the myotubes treated
with cancer cell CM (Fig. 5 I).
Taken together, these results can be summarized in the fol-
lowing model: Sirt1 down-regulation leads to NF-κB activation,
which can lead to increased expression of Nox4, an inducer of
oxidative stress that can in turn induce the expression of the
muscle-specific ubiquitin ligases via FOXO transcription factors,
to ultimately facilitate muscle atrophy (Fig. S5 A). To pharma-
cologically probe this pathway at each step, we used GKT137831
to inhibit Nox4 activity (Jiang et al., 2012), BMX-001 to scavenge
oxygen radicals (Archambeau et al., 2013), and AS1842856 to
inhibit FOXO1 activity (Zou et al., 2014). We observed that
MuRF1 (Trim63) and Atrogin-1 (Fbxo32) were down-regulated by
targeting all the arms of the pathway (Fig. S5 B).
Figure 5. SIRT1 stabilization diminishes ROS
levels in cachectic muscles. (A) ROS levels in
C2C12myotubes after treatment with cancer cell
CM with or without resveratrol for 8 h. (B) The
mRNA levels of Nox4 in the gastrocnemius muscles
from tumor cell-implanted mice (n = 3 for each
group) with and without resveratrol treatment.
(C) ChIP analyses demonstrating distal (−1,047)
and proximal (−369) Nox4 promoter region occu-
pancy by NF-κB. All groups are compared with the
control. (D) Nox4 mRNA levels in C2C12 myotubes
treated with cancer cell CM and NBD. (E) Nox4
mRNA levels in KPC mice muscles at 10, 15, and 25
wk of age (n= 3). (F) Brightfield microscopy images
(at 200×) demonstrating thinning of the myotubes
upon Nox4 overexpression. Scale bars represent
250 µm. (G) Immunoblot analysis of Nox4 over-
expressing myotube extracts depicting decrease in
the levels of myosin heavy chain. Tubulin was used
as a loading control. (H) Foxo1 and Foxo3 mRNA
levels in C2C12 myotubes upon Nox4 over-
expression for 48 h. (I) Nox4 mRNA level in C2C12
myotubes upon treatment with cancer cell CM
with or without adenoviral (Ad) expression of Sirt1.
Data are mean ± SEM compared with one-way
ANOVA with Bonferroni’s multiple comparisons
(A, B, C, D, and I) or Student’s t test (E and H). *, P <
0.05; **, P < 0.01; ***, P < 0.001. In vitro experi-
ments were verified in at least two independent
experiments.
Dasgupta et al. Journal of Experimental Medicine 8 of 17
Targeting Sirt1–Nox4 signaling in cancer cachexia https://doi.org/10.1084/jem.20190745
D
ow
nloaded from
 https://rupress.org/jem
/article-pdf/doi/10.1084/jem
.20190745/1044497/jem
_20190745.pdf?casa_token=O
l-pW
8P-YpM
AAAAA:O
otSTsQ
KJ521rR
R
bLO
oSJLAzhC
IhAnY919Kkp2TxrZEhZy26643vH
vW
nw
tD
C
A-Iew
leePVE0 by C
old Spring H
arbor Laboratory user on 01 June 2020
Induction of Nox4 expression in skeletal muscles drives
cancer-induced cachexia
To validate the cachectic role of Nox4 in an in vivo model, we
generated mice with tamoxifen-inducible conditional KO of
Nox4 in the skeletal muscles (Nox4fl/fl; ACTA1-Cre/Esr1; Fig. 6, A
and B). We then orthotopically implanted a mouse pancreatic
cancer cell line (KPC1245) into the pancreas of Nox4fl/fl; ACTA1-
Cre/Esr1 mice. The mice were then randomly divided into two
groups to be injected with tamoxifen (Nox4-KO) or control sol-
vent (Nox4-WT). Muscle-specific Nox4 KO substantially ame-
liorated tumor-induced cachexia, as measured by body weight
loss (Fig. 6 C); forelimb grip strength (Fig. 6 D); gastrocnemius
muscle weight (Fig. 6 E) and cross-sectional area (Fig. 6, F and
G); protein expression of MuRF1, ATROGIN-1, andmyosin heavy
chain (Fig. 6 H); and mRNA expression of Foxo1 and Foxo3
(Fig. 6 I).
Notably, there was no significant difference in tumor weights
between the two groups (Fig. S5 C), suggesting that the changes
inmuscle/body weight andmuscle functionwere due to muscle-
intrinsic effects. Nox4 KO did not have an impact on SIRT1 sta-
bilization (Fig. 6 H), highlighting the importance of Nox4 as a
downstream target of SIRT1. Taken together, these studies
suggest that targeting Nox4 in skeletal muscle may represent a
translatable strategy to treat cancer-induced cachexia.
Pharmacological inhibition of NOX4 rescues cancer cachexia in
mouse models
We next investigated the anticachectic potential of GKT137831
(henceforth referred to as GKT), a NOX4/NOX1 inhibitor in
phase 2 clinical trials for diabetes (NCT02010242) and primary
biliary cholangitis (NCT03226067). To achieve the same, we
orthotopically implanted human pancreatic cell line S2-013 in
Figure 6. Nox4 overexpression drives ca-
chexia in orthotopic pancreatic tumor mod-
els. (A) Schematic illustration of pancreatic
cancer cachexia model using Nox4fl/fl; ACTA1-cre/
Esr1 mice. (B) Immunoblot analysis of muscle
extracts from control and Nox4 KO mice de-
picting deletion of Nox4 in the muscles. Actin
was used as a loading control. (C) Change in
body weight of mice after 21 d of implantation.
(D) Grip strength of tumor-bearing Nox4WT and
Nox4 KO mice on day 18 after implantation.
(E) Postnecropsy gastrocnemius muscle weight
of healthy control (n = 10), tumor-bearing Nox4
WT (n = 8), and tumor-bearing Nox4 KO (n = 8)
mice. (F) Representative hematoxylin and eosin-
stained muscle sections depicting changes in the
muscle fiber cross-sectional area. Scale bars repre-
sent 25 µm. (G)Quantification of the gastrocnemius
muscle cross-sectional area of healthy controls and
tumor-implanted mice (n = 3). (H) Immunoblot
analyses of muscle extracts from Nox4WT andNox4
KO tumor-bearing mice. (I) Foxo1 and Foxo3 mRNA
levels in gastrocnemius muscles from control and
tumor-implantedmice (n = 5 for each group). Data
are mean ± SEM compared by one-way ANOVA
with Bonferroni’s multiple comparisons (C–E, G,
and I). *, P < 0.05; ***, P < 0.001.
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athymic nude mice and randomly segregated them into two
groups that received daily oral gavages of GKT or solvent control
starting 6 d after implantation (Fig. 7 A). 3 wk after implanta-
tion, mice were sacrificed and analyzed. GKT treatment signif-
icantly diminished the S2-013 tumor-induced cachexia by all
metrics that were measured, including body weight (Fig. 7 B);
gastrocnemius muscle weight and fiber cross-sectional area
(Fig. 7, D and H); body fat content (Fig. 7 E); grip strength
(Fig. 7 F); protein expression of MuRF1, Atrogin-1, and myosin
heavy chain (Fig. 7 I); and mRNA expression of Foxo1 and Foxo3
(Fig. 7 J). This correlated with a tumor-induced increase in ROS
in gastrocnemius as measured by electron paramagnetic reso-
nance (EPR) spectroscopy, which was diminished by GKT
treatment (Fig. 7 G). These results were further supported by
analysis of primary muscle samples from PDAC patients, which
showed a significant negative correlation between myofiber
cross-sectional area and NOX4 staining intensity (Fig. 7, K and
L). Of note, there was no difference in tumor weight (Fig. 7 C)
or muscle SIRT1 expression (Fig. 7 I) upon treatment with GKT,
confirming that these effects are independent of tumor burden
and downstream of SIRT1.
Cachexia is known to negatively impact patient survival;
therefore, we performed survival studies in our orthotopic im-
plantation model and observed significant survival benefit from
both resveratrol and GKT treatment (Fig. S5 D). These results
underscore the therapeutic potential of targeting this pathway
in the setting of pancreatic cancer cachexia.
Discussion
Cancer cachexia is a known contributor to poor quality of life
and mortality for cancer patients. Cancer cachexia not only
contributes to overall poor prognosis but also reduces a patient’s
ability to tolerate chemotherapy (Aapro et al., 2014). Since there
are currently no approved therapies for targeting cachexia in the
clinic, our studies establish the role of the Sirt1–Nox4 axis in
mediating cancer cachexia and demonstrate the utility of tar-
geting this pathway to treat this devastating syndrome.
Our studies demonstrate that SIRT1 stabilization in the
muscles successfully prevents muscle atrophy induced by pan-
creatic tumors in orthotopic implantation models that have been
well established as models of cancer cachexia and closely re-
semble many aspects of the human disease (Michaelis et al.,
2017; Shukla et al., 2014), such as loss in body and muscle
weight. The loss of SIRT1 expression in cachectic skeletal muscle
tissue was consistent across all systems examined, including a
C2C12 myotube model with cancer cell CM, orthotopic implan-
tation experiments, KPC mice with spontaneous tumors, and
primary muscle tissues from human PDAC cancer patients ob-
tained at autopsy. Abrogation of myotube thinning by exoge-
nous expression of SIRT1 in cultures demonstrated that SIRT1
loss is the cause, not a consequence, of cancer cell CM–induced
myotube wasting. Hence, our studies establish SIRT1 as a key
regulator of skeletal muscle mass in the setting of cancer ca-
chexia. While we did not observe a consistent alteration in the
expression levels of other sirtuins in cachectic muscles, we
cannot rule out the roles played by other sirtuins in tumor cells.
Multiple sirtuins have been shown to regulate aggressiveness in
tumor cells (Kugel et al., 2016; McGlynn et al., 2015) and may
indirectly impart cachectic functions. Nonetheless, our studies
establish that stabilizing SIRT1 expression may be an effective
therapy for cancer cachexia.
It is worth mentioning, however, that although SIRT1 stabi-
lization provided similar survival benefit as targeting NOX4
(Fig. S5 D), some studies have suggested that SIRT1 modulation
may have potential therapeutic limitations, due in part to a pro-
oxidant role or tumor growth–inducing properties (de la Lastra
and Villegas, 2007; San Hipólito-Luengo et al., 2017). Depending
on the cellular context, SIRT1 can act either as a tumor sup-
pressor or as a tumor promoter andmay have different signaling
targets in different cell types (Chen et al., 2005; Yeung et al.,
2004). For example, since pancreatic tumors have high rates of
glycolysis (Dang, 2010), we investigated whether resveratrol
affects the glucose uptake of pancreatic cancer cells. Resveratrol
decreased glucose uptake in S2-013 and T3M4 cells, an effect
that was reversed by Ex-527 (Fig. S5, E and F), implying a SIRT1-
dependent mechanism. Conversely, resveratrol increased glu-
cose uptake in myotubes exposed to cancer cell CM (Fig. S5 G),
highlighting the paradoxical metabolic consequences of per-
turbing SIRT1 in different cellular contexts. We speculate that
this might be due to the differences in the expression of the
glucose transporters between cancer cells and myotubes. The
expression of SLC2A1 (GLUT1) and SLC2A4 (GLUT4) was signifi-
cantly higher in the former (Fig. S5 H). Previous studies have
shown that resveratrol inhibits GLUT1 in cancer cells but in-
creases GLUT4 translocation to the membrane in myoblasts, and
this differential effect might explain our result (Penumathsa
et al., 2008; Zambrano et al., 2019). However, further work is
warranted in this direction.
In our studies with the in vitro models of cancer cell CM–
inducedmyodegeneration, RNA-seq analysis identified NF-κB as
the most significantly altered pathway in myotubes upon CM
exposure. This was in line with classical studies in cachexia that
implicated NF-κB as the master regulator of ubiquitin protea-
some in cancer-induced muscle atrophy (Cai et al., 2004; Han
et al., 1999). Although previous studies have demonstrated an
association between NF-κB activation and the proteins in the
ubiquitin proteasome pathway (Cai et al., 2004; Whitehouse and
Tisdale, 2003), a direct mechanism was still not known. Here,
we elucidate the mechanistic regulation of muscle wasting
downstream of diminished SIRT1 expression and NF-κB activa-
tion. Downstream of NF-κB activation, we observed tumor cell-
induced expression of FOXO proteins, which are known to be
regulated by oxidative and metabolic stress (Klotz et al., 2015).
Based on the previous evidence highlighting the antioxidant
functions of SIRT1 (Jang et al., 1997) and the influence of oxi-
dative stress on muscle wasting (A´brigo et al., 2018; Scicchitano
et al., 2018), we next asked if the observed resveratrol-
dependent decrease in muscle atrophy was due to altered
redox balance via SIRT1-dependent attenuation of NF-κB acti-
vation. Indeed, we found that resveratrol inhibits cancer cell
CM–induced activation of NF-κB and that direct inhibition of NF-
κB reduces the cancer cell CM–induced expression of MuRF1 and
Atrogin-1 ubiquitin ligases. This highlights the role of SIRT1 as
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Figure 7. Pharmacological inhibition of NOX4 rescues muscle wasting in a cancer cachexia model. (A) Schematic illustration of S2-013 tumor cell
implantation and GKT137831 (GKT) therapy initiation in athymic nude mice. (B) Change in the mouse body weight 21 d after implantation for healthy controls
(n = 9), healthy controls with GKT (n = 4), S2-013 implanted (n = 9), and S2-013 implanted with GKT treatment (n = 10). (C and D) Postnecropsy tumor weight
(C) and gastrocnemius muscle weight (D) for S2-013–implanted mice with and without GKT treatment. (E) Body fat percentage at day 18 in tumor-bearingmice
with and without GKT treatment. (F) Grip strengthmeasurements on day 18 after implantation. (G) Gastrocnemius muscle ROSmeasurement by EPR in tumor-
bearing mice with and without GKT treatment (n = 5 for each group). (H) Representative images of hematoxylin and eosin–stained gastrocnemius muscle cross
sections. Quantification of the cross-sectional area measured via ImageJ (n = 3). Scale bars represent 100 µm. (I) Immunoblot analysis of gastrocnemius muscle
extracts from mice with indicted treatments. (J) Foxo1 and Foxo3 mRNA levels in gastrocnemius muscles from mice with indicted treatments (n = 3 for each
group). (K) Representative images of NOX4-stained human muscle specimens. Scale bars represent 25 μm. (L) Correlation of Nox4 staining histoscore and
muscle fiber cross-sectional area in skeletal muscles from human pancreatic cancer patients (n = 47). (M) Schematic illustration of the action of resveratrol and
GKT as potential therapeutic interventions in combating muscle wasting in cancer. Data are mean ± SEM compared with one-way ANOVA with Bonferroni’s
multiple comparisons (B, D–H, and J) or Student’s t test (C). *, P < 0.05; **, P < 0.01; ***, P < 0.001.
Dasgupta et al. Journal of Experimental Medicine 11 of 17
Targeting Sirt1–Nox4 signaling in cancer cachexia https://doi.org/10.1084/jem.20190745
D
ow
nloaded from
 https://rupress.org/jem
/article-pdf/doi/10.1084/jem
.20190745/1044497/jem
_20190745.pdf?casa_token=O
l-pW
8P-YpM
AAAAA:O
otSTsQ
KJ521rR
R
bLO
oSJLAzhC
IhAnY919Kkp2TxrZEhZy26643vH
vW
nw
tD
C
A-Iew
leePVE0 by C
old Spring H
arbor Laboratory user on 01 June 2020
a key antagonist of NF-κB-induced muscle wasting and the
pathophysiological importance of decreased muscle SIRT1 ex-
pression in pancreatic cancer cachexia.
Since SIRT1 is a known regulator of oxidative stress (Khan
et al., 2012), we screened for redox regulators that were induced
by cancer cell CM. Our screen identified Nox4 to be the key
oxidative stress regulator that was induced in the muscles of
tumor-bearing mice, an effect that was abolished by resveratrol
treatment. While previous studies have shown that Nox4 is
regulated by NF-κB in different models (Manea et al., 2010;
Williams et al., 2012), we demonstrate that Nox4 promoter oc-
cupancy by NF-κB and NF-κB activity are significantly induced
by tumor cell CM, and the effect is diminished by resveratrol.
Furthermore, muscle-specific Nox4 KO and pharmacological
blockade of Nox4 in tumor-bearing mice abolished tumor-
induced muscle atrophy and reduced Nox4-induced Foxo1
and Foxo3 expression. These studies demonstrate that SIRT1
regulates oxidative stress and atrophy in skeletal muscles by
NF-κB–mediated expression of Foxo1 and Foxo3, via NOX4. It
remains to be identified what down-regulates SIRT1 expres-
sion. Transforming growth factor β, which has been shown to
induce Nox4 (Carmona-Cuenca et al., 2008), is a potential
regulator. However, in our model, it failed to decrease the ex-
pression of Sirt1 (Fig. S5 I). We speculate that the modulation of
energy homeostasis and metabolism in cachectic muscles might
be responsible for the alteration in Sirt1 levels.
The clinical relevance of these findings is underscored by the
observed significant negative correlation of NOX4 expression
with the skeletal muscle fiber cross-sectional area in human
pancreatic cancer patients. NOX4 has also been reported to drive
tumor progression downstream of activated KRAS (Ju et al.,
2017) and promote epithelial-mesenchymal transition in pan-
creatic cancer cells (Hiraga et al., 2013). These findings suggest a
potential dual role for NOX4 inhibition in pancreatic cancer
therapy. However, we did not observe a significant reduction in
tumor burden upon Nox4 inhibition via GKT. The contrasting
results might be due to the inherent characteristics of the cell
lines that were used or the insufficient dosage of the compound
to impact tumor burden. Of note, the role of SIRT1 in cancer is
ambiguous. Depending on the cellular context, SIRT1 could act
either as a tumor suppressor or as a tumor promoter and may
have different signaling targets in different cancer types (Chen
et al., 2005; Yeung et al., 2004). These studies, along with our
present study, suggest the potential of NOX4, but perhaps not
the upstream signaling regulator Sirt1, as a therapeutic target for
future clinical studies. Of note, the NOX4 inhibitor GKT137831 is
already in clinical trials for various diseases. Interestingly, Nox4
is also up-regulated in angiotensin II–induced muscle wasting,
implying the possibility of a common pathway (Kadoguchi et al.,
2018) inmultiplemuscle disorders. Since other disorders such as
muscular dystrophy also show increased muscle NF-κB or NOX4
activity (Whitehead et al., 2010), GKT could be effective in
treating muscle wasting induced by a variety of pathologies, a
possibility that warrants further investigation.
Overall, this study demonstrates that tumor-induced muscle
wasting was mediated by the SIRT1 loss and the resulting acti-
vation of NF-κB, which in turn induces the expression of Nox4
in skeletal muscles, leading to the induction of protein degra-
dation pathways (Fig. 7 M). These findings provide new insights
into the mechanisms that underlie weight and muscle loss
in cancer cachexia. These studies provide novel therapeutic
opportunities for targeting tumor-induced skeletal muscle
wasting.
Materials and methods
Cell culture and reagents
Pancreatic cancer cell lines T3M4 and S2-013 were generous
gifts from Dr. Michael A. Hollingsworth (Eppley Institute, UNMC,
Omaha, NE; Chaika et al., 2012). hTERT-HPNE (HPNE) cells were a
kind gift from Dr. Michel M. Ouellette (UNMC, Omaha, NE; Lee
et al., 2003). Cancer cell line C26 and HEK293T cells was obtained
from ATCC. Cell lines were validated by STR profiling by the
Genetics Core at University of Arizona. Mouse KPC pancreatic
cancer cell lines were derived from the transgenic mouse models
described below. All cell lines were cultured in DMEM (Sigma-
Aldrich) with 10% FBS, 100 IU/ml penicillin, and 100 µg/ml
streptomycin and incubated at 37°C in a humidified incubator
with 5% CO2. C2C12 myoblasts were purchased from ATCC and
cultured in DMEM with 10% FBS until confluent. After reaching
confluency, the myoblasts were differentiated in DMEM with 2%
horse serum and 1 µg/ml insulin for 72 h, as previously described
(Shukla et al., 2015). Resveratrol for in vitro studieswas purchased
from Sigma-Aldrich, and stocks were diluted in DMSO. Ex-527
was purchased from Santa Cruz Biotechnology. NBD peptide/
NF-κB blocker was purchased from Enzo Life Sciences. FOXO1
inhibitor AS-1842856 and Nox4 inhibitor GKT 137831 were pur-
chased from Cayman Chemical Company. BMX-001 was provided
by Dr. Rebecca Oberley-Deegan (UNMC, Omaha, NE).
Lentivirus and adenovirus transfections
Cell transfections for producing replication-incompetent lenti-
virus were performed by using Turbofect from Thermo Fisher
Scientific, following the manufacturer’s protocol. Short hairpin
RNA constructs for stable knockdown of Sirt1 were obtained
from Sigma-Aldrich. After transfection, cells were selected using
puromycin. Human NOX4 adenovirus was provided by Dr. Me-
lissa Teoh-Fitzgerald (UNMC, Omaha, NE). GFP-expressing ad-
enovirus was provided by Dr. Matthew Zimmerman (UNMC,
Omaha, NE).
Mouse Sirt1 adenovirus was purchased from Applied Biolog-
ical Materials. C2C12 myotubes were differentiated for 48 h, and
the differentiated myotubes were infected with adenovirus with
a multiplicity of infection of 200.
Cancer cell CM preparation
For CM preparation, S2-013, HPNE, KPC1245, KPC1199, and
T3M4 cell lines were seeded and cultured in DMEM with 10%
FBS as previously described (Shukla et al., 2015). After cells
became 70–80% confluent, cells were washed twice with 1× PBS
and cultured in serum-free DMEM for 24 h. The media was then
collected and centrifuged at 3,000 rpm for 10 min, and the su-
pernatant was collected in a fresh tube to be either used im-
mediately or stored at −80°C for future use. CM was prepared
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from equal number of cancer cells for each cell line. CM was
reconstituted with 2% horse serum 1 µg/ml insulin before
treating myotubes.
Cell viability assays
Cell viability was determined by MTT assays 72 h after treat-
ment, as described previously (Shukla et al., 2015).
RNA isolation and quantitative RT-PCR
Total RNA was extracted from cells or tissue lysates by using
TRIzol reagent (Invitrogen) as previously discussed (Shukla
et al., 2015). cDNA was synthesized using Verso-cDNA synthe-
sis kit (Thermo Fisher Scientific) according to the manu-
facturer’s protocol. Quantitative RT-PCR was performed using
SYBR Green master mix (Applied Biosystems). Actb (codes for
β-actin) was used as an internal control. Total RNA for RNA-seq
analysis was isolated using RNAeasy columns (Qiagen), as per
the manufacturer’s protocol. Relative gene expression analysis
was performed by using the ΔΔCt method, as described previ-
ously (Shukla et al., 2015). The primer sequences are provided in
Table S2.
ChIP assay
The ChIP assay was performed as described previously (Shukla
et al., 2017). Briefly, ChIP assays were performed by using an
antibody against p65 subunit of NF-κB (clone F-6), using IgG as a
control. A total of 3 µl purified chromatin for each reaction was
used for quantitative PCR (qPCR) analysis. The qPCR analysis
was performed by Applied Biosystems QuantStudio 5 real-time
PCR system. Each reaction was performed in triplicate. The
threshold cycle values obtained for each genomic region were
used for further analysis. For ChIP qPCR analysis, threshold
cycle values were normalized to the input control and repre-
sented as a fold increase over the enrichment detected using IgG.
Immunohistochemistry
Immunohistochemistry was performed as described previously
(Shukla et al., 2015). We used Novolink Polymer (Leica), as per
the manufacturer’s instructions. Muscle sections prepared from
human patient tissues were stained with SIRT1 antibody (Cell
Signaling Technology) and NOX4 antibody (Abcam). Each mus-
cle fiber in a cross-sectional field of view was given an intensity
score by evaluating staining intensity of positive staining (0 =
none, 1 = weak, 2 = intermediate, 3 = strong). The histoscore was
calculated by multiplying the percentage of fibers (0–100) with
the particular score by its corresponding intensity score (0–3).
All the scores in a given section were added, and the value was
then divided by 100 to attain a score between 1 and 3.
Immunoblotting
Protein isolation and Western blotting were performed as de-
scribed previously (Shukla et al., 2015). Briefly, cells were
washed twice with PBS and lysed in radioimmunoprecipitation
assay lysis buffer by shaking on ice for 10 min. Then, the lysates
were centrifuged at 13,000 rpm for 5 min, and the supernatant
was collected. Protein concentration was measured by the
Bradford assay. Equal amounts of protein were loaded into the
SDS-PAGE gel for immunoblotting. Primary antibodies against
MuRF1, ATROGIN-1, and p65 (NF-κB; Santa Cruz Biotechnology);
SIRT1, FOXO3a, FOXO1, and Acetyl-p65 (K310; Cell Signaling
Technology); tubulin, actin (JLA20), and MyHC (Developmental
Studies Hybridoma Bank); and NOX4 (Abcam) were used for
probing specific proteins. Loading control was run in parallel on
separate gels for each experiment.
SIRT1 activity assay
SIRT1 activity was measured in myotubes b–y using a SIRT1
activity assay kit, following the manufacturer’s protocol (Sigma-
Aldrich). C2C12 myotubes were treated with S2-013 and T3M4
cancer cell CM for 24 h, and SIRT1 activity was measured.
NF-κB reporter assay
NF-κB luciferase adenovirus was purchased fromVector Biolabs.
C2C12 cells were seeded and differentiated as previously men-
tioned in 6-well plates. C2C12 myotubes were then treated with
cancer cell CM for 6 h with and without resveratrol. After 6 h,
cells were lysed and assayed for luciferase activity using Prom-
ega Luciferase Reporter Assay according to the manufacturer’s
instructions.
Caspase 3/7 activity assay
C2C12 myotubes were treated with control or cancer cell CM.
Caspase 3/7 activity assay was performed using Promega Cas-
pase Glo-kit as previously described (Shukla et al., 2015).
Metabolomics of CM
Serum-free DMEMwas added to HPNE and S2-013 cells, and the
CM was collected after 24 h. Polar metabolites were extracted
from the CM and analyzed via liquid chromatography–coupled
tandem mass spectrometry as previously described (Shukla
et al., 2017).
Animal studies
Orthotopic studies
All animal experiments performed in this study were approved
by the UNMC Institutional Animal Care and Use Committee.
Female athymic nude mice (NCr-nu/nu) were bred in-house,
and 6–8-wk-old mice were used for orthotopic implantations.
0.5 × 106 S2-013 scrambled control, S2-013 shSIRT1-A, or S2-013
shSIRT1-B cells were injected into the mouse pancreas, and 7 d
after implantation, mice were randomized into groups of 10
animals each. Age- and gender-matched mice, without any tumor
cell injection, were used as healthy controls. Trans-resveratrol
(Cayman Chemical) was solubilized in 1.5% methylcellulose with
vigorous vortexing (Shadfar et al., 2011). Beginning on day 7, mice
received a daily oral gavage of 200 mg/kg trans-resveratrol de-
livered using a 20G gavage needle. Tumor volumes and body
weights were recorded regularly. After 14 d of treatment, all mice
were euthanized, and tumor weight, tumor volume, gastrocne-
mius muscle weight, and body weight were measured. Tumor
tissue, liver, spleen, and muscles were flash frozen in liquid ni-
trogen and formalin fixed for further analysis.
For GKT137831 studies, 0.25 × 106 S2-013 cells were im-
planted in the pancreas of athymic nude mice. After 7 d of
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implantation, the mice were randomized into two groups.
GKT137831 was solubilized in 1.2% of methylcellulose and 0.1% of
polysorbate 80 and administered to 10 tumor-bearing mice at a
concentration of 60 mg/kg via daily oral gavage. The other
mouse cohort was gavaged with the solvent solution. To test for
toxicity, we also gavaged four healthy mice with GKT137831. An
independent cohort of similarly treated mice were used for
survival studies.
For studies with C26 cells, 0.5 × 106 cells were implanted
subcutaneously in athymic nude mice. Tissues were collected
21 d after implantation.
KPC tissues
The muscles of 10-, 15-, and 25-wk-old littermate controls or
mice from C57BL/6-congenic KPC spontaneous progression
model of pancreatic cancer and littermate controls were har-
vested by euthanizing the mice at the respective ages.
Transgenic mouse model
C57BL/6 mice expressing tamoxifen-inducible muscle-
specific Cre recombinase (ACTA1-cre/Esr1) were obtained
from the Jackson Laboratory (McCarthy et al., 2012). Nox4-
floxed mice have been described previously (Kuroda et al.,
2010). These mice were crossbred to get the desired mice
genotype (Nox4fl/fl; ACTA1-cre/Esr1). Nox4 KO in the skeletal
muscles was induced by administration of tamoxifen for 5
consecutive days at a concentration of 75 mg/kg, as suggested
by the Jackson Laboratory. Littermates were used as controls
for the studies.
0.25 × 105 KPC1245 cells were implanted into the pancreas of
male age-matched Nox4fl/fl; ACTA1-cre/Esr1 mice or littermate
controls. After implantation, mice were randomized into two
groups of eight mice each, and one group was injected with ta-
moxifen to induce Nox4 deletion in the muscles.
Mouse body fat measurement
Fat percentage in each mouse was measured by dual-energy
x-ray absorptiometry scanning on the 18th day after implanta-
tion as previously described (Henry et al., 2014). Mice were
anesthetized using a mixture of isoflurane and oxygen and
placed on the positioning tray in the imager. Mice were scanned
using a Lunar PIXImus densitometer (GE Medical-Lunar).
Patient samples
Skeletal muscle specimens (pectoral or diaphragm) collected
from pancreatic cancer patients were obtained from the UNMC’s
Tissue Bank through the Rapid Autopsy Program for Pancreas.
The tissues were harvested with appropriate consent, as ap-
proved by the UNMC Institutional Review Board under appli-
cation IRB 091–01.
Measurement of grip strength
A grip strength meter (Columbus Instruments) was used to as-
sess forelimb grip strength as previously described (Shukla
et al., 2015). On the 18th day of treatment, we acclimatized
mice to the procedure room for 15 min and measured grip
strength as per the manufacturer’s instructions.
Detection of ROS in muscles
EPR spectroscopy was used to detect oxygen radicals in the muscle
tissues as previously described (Case et al., 2013). Briefly, gastroc-
nemiusmuscle tissues were harvested and incubated for 1 h at 37°C
with the cell-permeable superoxide (O2˙−)-sensitive spin probe 1-
hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrrolidine (200
μmol/liter; Noxygen Science Transfer and Diagnostics) in a Krebs-
Hepes buffer (pH 7.4) supplemented with the metal chelators
diethyldithiocarbamate (5 µM) and deferoxamine (25 µM). The
EPR–1-hydroxy-3-methoxycarbonyl-2,2,5,5-tetramethylpyrroli-
dine spectra were normalized to the gastrocnemius muscle
weight.
ROS assay
ROS levels in cells were determined as described previously
(Abrego et al., 2017). Briefly, ROS levels were determined by using
oxidation-sensitive fluorescent dye 29,79–dichlorofluorescein di-
acetate (DCFDA). C2C12 cells were seeded at 3.0 × 104 cells perwell
in a clear-bottom black 96-well plate. The C2C12 myotubes were
then differentiated and treated with the CM for 8 h. The medium
was replaced with fresh DMEM containing 20 µM DCFDA, and
cells were incubated at 37°C for 30 min. H2O2 along with DCFDA
was used as a positive control, and 29,79-Bis(2-carboxyethyl)-5(6)-
carboxyfluorescein was used as a negative control. The cells were
washed with PBS, and DCFDA fluorescence was measured at 485-
nm excitationwavelength and 529-nm emissionwavelength using
a BioTek Cytation 3 plate reader (BioTek Instruments).
Glucose uptake assay
Glucose uptake assay was performed as previously described
(Abrego et al., 2017). Briefly, S2-013 and T3M4 cells were seeded
at a density of 5 × 104 cells/well in 12-well plates. After overnight
attachment, the cells were treated with resveratrol (25 µM) or
Ex-527 (0.5 µM) for 24 h. The cells were then starved for 2 h in
DMEM without glucose, glutamine, pyruvate, and FBS. [3H]2-
deoxy glucose was then added to the wells, incubated for 20min,
washed once with 1× PBS, and then lysed with 1% SDS. The ly-
sates were then counted for tritium incorporation by a scintil-
lation counter, which was then normalized according to cell
counts. For C2C12 myotubes, glucose uptake was performed
after the differentiated myotubes were treated for 24 h, and
values were normalized with the respective protein content.
RNA-seq analysis
RNA-seq analysis was performed on C2C12-differentiated my-
otubes treated with S2-013-CM with or without resveratrol. All
gene sets in GMT file format with Entrez IDs for Mus musculus
were downloaded from http://ge-lab.org/gskb/. The gene set for
TFactS (http://www.tfacts.org/) was chosen from the list and
was made into a separate file, converted into gene symbols
through Ensembl BioMart (https://www.ensembl.org/biomart/
martview), and predicted genes and pseudogene were removed
(n = 10) before being used by GSEA2 v2.2.3 with 1,000 permu-
tations in the classic scoring scheme. A heatmap of the nor-
malized enrichment score (NES) was produced in R v3.3.2 with
the gplots package after filtering for the top 25% most variable
gene sets. RNA-seq data files for one sample each of untreated
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C2C12 myotubes or C2C12 myotubes treated with S2-013-CM
with or without resveratrol for 24 h have been submitted to GEO
repository under the accession no. GSE147554.
Online supplemental material
Fig. S1 demonstrates the expression of sirtuins and cachectic
markers in various cancer models, including the spontaneous
progressionmouse model of pancreatic cancer. Fig. S2 illustrates
the expression levels of various sirtuins and metabolites de-
pleted in the cancer cell CM and their effect on muscle wasting.
Fig. S3 shows the effect of pharmacological manipulation of SIRT1
onmarkers of adipose tissuemuscle wasting and redox regulators.
Fig. S4 presents the expression levels of NOX4 and atrophy
markers upon Sirt1 stabilization and NF-κB inhibition. Fig. S5
elucidates the SIRT1-NOX4 signaling cascade by using various
pharmacological inhibitors of key regulators. Table S1 shows pa-
tient characteristics. Table S2 shows primer sequences used.
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Figure S1. Muscle wasting with disease progression in KPC mice and colon cancer cachexia model. (A) Sirtuin mRNA expression in gastrocnemius
muscles from KPC mice at 10, 15, and 25 wk of age. (B) Gastrocnemius muscle weights and (C) hematoxylin and eosin–stained pancreas sections of control and
KPC mice at 10, 15, and 25 wk of age, (D) mRNA expression of Trim63 and Fbxo32 in muscles of control and KPC mice at 10, 15, and 25 wk of age. (E) Sirtuin
mRNA expression in gastrocnemius muscles from C26 tumor-bearing mice at 21 d after implantation (n = 5 in each group). Scale bars represent 93.4 µm. Data
are mean ± SEM compared with Student’s t test. *, P < 0.05; **, P < 0.01.
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Figure S2. In vitro characterization of sirtuins andmetabolite abundance. (A) Sirt2, Sirt3, Sirt4, Sirt5, Sirt6, and Sirt7mRNA expression in control myotubes
and myotubes treated with S2-013, T3M4, KPC1245, and KPC1199 CM for 24 h. (B) Sirt1 activity in control myotubes and myotubes treated with S2-013 and
T3M4 CM for 24 h. (C) Relative metabolite levels in DMEM and HPNE and S2-013 CM. (D) Relative protein content of C2C12 myotubes treated with DMEM and
HPNE CM, S2-013 CM, and S2-013 CM + supplements (Supp; metabolites that decreased >25% in S2-013 CM relative to DMEM). (E) Caspase 3/7 activity in
control and cancer cell CM–treated C2C12 myotubes. Data are mean ± SEM compared with one-way ANOVA with Dunnett’s (A–D) multiple comparisons and
Student’s t test (E). *, P < 0.05; **, P < 0.01; ***, P < 0.001. In vitro experiments were verified in at least two independent experiments.
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Figure S3. Effect of SIRT1 manipulation in cancer cells on adipose tissue muscle wasting and redox regulators. (A) Cell survival assay of S2-013 cells
treated with resveratrol (50 µM), Ex-527 (0.1 µM), or both for 72 h. (B) Gastrocnemius muscle weight of control and PBS-injected mice. (C) Relative mRNA
levels of Zag (Zinc α2-glycoprotein) and Ucp 1-3 in adipose tissues of tumor-bearing mice with and without resveratrol treatment. (D) SIRT1 staining in
gastrocnemius muscles of healthy controls and tumor-bearing mice treated with vehicle control or resveratrol. Scale bars represent 250 µm. (E) The mRNA
levels of redox regulators in gastrocnemius muscles of tumor-bearing mice with and without resveratrol treatment (n = 3 for each group): Nox1–Nox3, su-
peroxide dismutase 1–3 (Sod1–Sod3), glutathione peroxidase 1–4 (Gpx1–Gpx4), Catalase, and thioredoxin 1–3 (Trdxn1–Trdxn3). Data are mean ± SEM compared
with one-way ANOVA with Bonferroni’s (A, C, and E) multiple comparisons or Student’s t test (B). *, P < 0.05, **, P < 0.01; ***, P < 0.001. In vitro experiments
were verified in at least two independent experiments.
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Figure S4. Evaluation of NOX4 and atrophymarkers upon SIRT1 stabilization and NF-κB inhibition. (A) Representative images of NOX4-stained sections
of gastrocnemius muscles of S2-013-implanted mice with and without resveratrol treatment. Scale bars represent 116.9 µm. (B) Immunoblots of C2C12
myotubes treated with S2-013 CM with and without Sirt1 overexpression. (C) mRNA levels of Trim63 and Fbxo32 in C2C12 myotubes treated with cancer cell
CM and NBD for 24 h. (D)mRNA levels of Nox4, Foxo1, Foxo3, Fbxo32, and Trim63 in the gastrocnemius muscles of healthy control and C26 tumor-bearing mice
(n = 5 in each group). Data are mean ± SEM compared with one-way ANOVA with Bonferroni’s (C) multiple comparisons or Student’s t test (D). *, P < 0.05; **,
P < 0.01; ***, P < 0.001. In vitro experiments were verified in at least two independent experiments.
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Figure S5. The SIRT1–NOX4 axis of myodegeneration. (A) Schematic illustration of the proposed pathway. (B) mRNA levels of Trim63 and Fbxo32 in C2C12
myotubes treated with control or cancer cell CM with solvent control or GKT137831 (10 µM), AS1842856 (0.1 µM; FOXO1 inhibitor), and BMX-001 (1 µM) for 24 h.
(C) Postnecropsy tumor weights from tumor-implanted Nox4 WT and Nox4 KO mice. (D) Kaplan-Meier survival analysis of S2-013 tumor-bearing mice treated
solvent control, GKT137831 (GKT), or resveratrol (n = 10 mice in each group). (E) Relative glucose uptake in S2-013 and T3M4 cells upon resveratrol treatment (50
µM) for 24 h. (F) Glucose uptake in S2-013 and T3M4 cells upon Ex-527 (0.5 µM) treatment for 24 h. (G) Glucose uptake in C2C12 myotubes upon treatment with
cancer cell CM with solvent control or resveratrol for 24 h. (H)mRNA expression of SLC2A1-4 in S2-013 cells and C2C12 myotubes. (I)mRNA expression of Sirt1 in
the C2C12 myotubes upon treatment with solvent control or TGF-β (20 ng/ml) for 24 h. Data are mean ± SEM compared with one-way ANOVA with Bonferroni’s
(B and G) multiple comparisons, Student’s t test (C, E, F, H, and I), or log-rank (Mantel-Cox) test (D). *, P < 0.05; **, P < 0.01; ***, P < 0.001. In vitro experiments
were verified in at least two independent experiments.
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Tables S1 and S2 are provided online as separate Word documents. Table S1 lists patient characteristics. Table S2 lists primer
sequences used.
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